I think the potential sales of the Molteno3 and AlphaRET products offer massive potential in a multi-billion dollar market, and that a $50Million capitalisation is peanuts compared to the potential. Imagine if you were sitting in North America or Europe, trying top service the Glaucoma and Macular degeneration market, and you heard of the potential to pick up some unique technology for $50M (plus a market premium). Very cheap in USD / CHF.
Nova Eye Medical (EYE) Discussion, page-1841
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.64M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $65.26K | 412.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 76733 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 239407 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |